ClinicalTrials.gg
TerminatedNCT01077154Updated Sep 28, 2021Results posted

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

A Phase 3 interventional study of Placebo and Denosumab in Breast Cancer, sponsored by Amgen. Terminated at 459 sites in 39 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated: Amgen decision following Primary Analysis. Not due to safety reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,509
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Enrollment
Largest of 24
4,509 · median 53
Started
2010
the only one that year
Phase 3
9 of 24
none open now
Registered
7th of 24
by date
Lead sponsor
8 of 24
Amgen

Among the 24 studies testing denosumab in Breast Neoplasms, this one has the largest enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.

Read the detailed description

Eligible participants were randomized in a 1:1 ratio to receive denosumab 120 mg or placebo subcutaneously (SC) for up to 5 years. Randomization was stratified based on:

  1. Breast cancer therapy/lymph node (LN) status: neoadjuvant therapy/any LN status versus adjuvant therapy/LN negative (based on axillary LN dissection, or based on sentinel node status) versus adjuvant therapy/LN positive
  2. Hormone receptor (estrogen receptor [ER]/progesterone receptor [PR]) status: ER and/or PR positive versus ER and PR negative
  3. Human epidermal growth factor receptor 2 (HER-2) status: HER-2 positive versus HER-2 negative
  4. Age: \< 50 years versus ≥ 50 years
  5. Geographic Region: Japan versus Other regions.

The primary analysis was conducted after all enrolled participants had the opportunity to complete 5 years of treatment from study day 1.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Early Stage Breast Cancer
  • Bone Metastasis
  • Adjuvant treatment
  • Neoadjuvant treatment
  • Denosumab
  • Stage II breast cancer
  • Stage III breast cancer
  • Stage IIA breast cancer
  • Stage IIB breast cancer
  • Stage IIIA breast cancer
  • Stage IIIB breast cancer
  • Stage IIIC breast cancer
  • Early breast cancer
  • Breast Tumors
  • Breast Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, American Joint Committee on Cancer (AJCC) stage II or III breast cancer
  • High risk of breast cancer recurrence, defined as documented evidence of one or more of the following criteria:

    i) evidence of breast cancer in regional lymph node(s) (LN) (node-positive disease); Nodal micrometastases only are not considered node positive ii) Tumor size > 5 cm (T3) or locally advanced disease (T4)

  • Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and status
  • Subjects must be receiving or be scheduled to receive standard of care systemic or neoadjuvant chemotherapy and/or endocrine therapy and/or HER-2 targeted therapy
  • For subjects receiving adjuvant therapy only:
  • subjects must have undergone complete resection of the primary tumor with clean surgical margins, or subjects must have undergone resection of the primary tumor and be scheduled for further treatment of the primary tumor with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization
  • Time between definitive surgery and randomization must be ≤ 12 weeks. Definitive surgery may include secondary interventions (e.g. to clear inadequate surgical margins)
  • Subjects with node positive disease must have undergone treatment of axillary LN with curative intent, or subjects must be scheduled for further treatment of regional lymph nodes with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization
  • Subjects must not have received prior neoadjuvant treatment. Endocrine treatment for less than 30 days prior to surgery is not considered prior neoadjuvant treatment
  • For subjects receiving neoadjuvant therapy only:
  • Time between start of neoadjuvant treatment and randomization must be ≤ 8 weeks and subjects must be scheduled to undergo definitive treatment (including surgery and/or radiotherapy) with curative intent within approximately 9 months of starting neoadjuvant treatment
  • Female subjects with age ≥ 18 years
  • Subjects with must have a negative pregnancy test within 14 days before randomization
  • Serum calcium or albumin-adjusted serum calcium ≥ 2.0 mmol/L (8.0 mg/dL) and ≤ 2.9 mmol/L (11.5 mg/dL)
  • (ECOG) performance status of 0 or 1
  • Written before any study-specific procedure is performed

Exclusion criteria

Exclusion Criteria:

  • Prior or current evidence of any involvement of any distant site
  • History of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the current diagnosis
  • Osteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six months
  • Any prior or synchronous (other than breast cancer), except i) Malignancy treated with curative intent and with no evidence of disease for ≥ 5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician ii) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Active infection with virus or virus
  • Known infection with (HIV)
  • Prior history or current evidence of osteomyelitis/osteonecrosis of the jaw
  • Active dental or jaw condition which requires oral surgery
  • Planned invasive dental procedure for the course of the study
  • Non-healed dental or oral surgery
  • Use of oral bisphosphonates within the past 1 year
  • Prior or current IV bisphosphonate administration
  • Prior administration of denosumab
  • Subject currently is enrolled in or has not yet completed at least 30 days since ending other device or investigational drug study(s), or subject is receiving other investigational agent(s)
  • Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
  • Subject is of child bearing potential and is not willing to use, in combination with her partner, 2 highly effective methods of or abstinence during treatment and for 5 months after the end of treatment
  • Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures.
  • Any major medical or psychiatric disorder that in the opinion of the investigator prevent the subject from completing the study or interfere with the interpretation of the study results
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,509 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.

    Drug: Placebo

  • Experimental
    Denosumab

    Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.

    Drug: Denosumab

Interventions

  • DrugPlacebo

    Administered subcutaneously for up to 5 years

  • Administered subcutaneously for up to 5 years

    Also known as: XGEVA®

06

What researchers measure

Primary outcomes

  1. Bone Metastasis-free Survival (BMFS)

    BMFS time was defined as the time interval from the randomization date to the first occurrence of bone metastasis or death from any cause, whichever came first. Participants last known to be alive with no bone metastasis were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first occurrence of bone metastasis before randomization were censored at their randomization date. Bone metastasis must have been confirmed by central imaging analysis or by biopsy, Evidence of disseminated tumor cells in bone marrow was not sufficient for determination of disease recurrence. Development of new primary malignancy in bone was not considered as bone metastasis. Since the median BMSF time could not be estimated due to low number of events, the percentage of participants with an event (i.e., bone metastasis or death) is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.

Secondary outcomes

  1. Disease-free Survival (DFS)

    DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date. Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.

  2. Disease-free Survival (DFS) in the Postmenopausal Subset

    DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date. Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time in the postmenopausal subset could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.

  3. Overall Survival

    Overall survival (OS) time was defined as the time interval from the randomization date to the date of death from any cause. Participants last known to be alive were censored at their last contact date. Since the median time to overall survival could not be estimated at the time of the final analysis due to low numbers of events, the percentage of participants with an event (i.e., death) is reported.

    Time frame: From randomization until the end of study; median (minimum, maximum) time on study was 72.7 (0, 92) and 72.3 (0, 92) months in each treatment group respectively.

  4. Distant Recurrence-free Survival

    Distant recurrence-free survival (DRFS) was defined as the time interval from the randomization date to the date of first observation of distant disease recurrence or death from any cause, whichever came first. Participants last known to be alive, who had not experienced distant disease recurrence, were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first distant recurrence before randomization were censored at their randomization date. Distant disease recurrence includes confirmed bone metastasis and extraosseous disease other than local-regional disease recurrence. Development of non-breast cancer new primary malignancy was not considered as distant disease recurrence. Since the median time to DRFS could not be estimated due to the low number of events, the percentage of participants with an event (i.e., distant recurrence or death) is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.

07

Results

Posted Oct 3, 2018

Participant flow

Participants were enrolled at 407 centers in Australia, Western Europe, Eastern Europe, Israel, North America, Asia, South America, South Africa, and Turkey from 02 June 2010 to 24 August 2012.

Participant flow — Overall Study
MilestonePlaceboDenosumab
Started22532256
Received study drug22292230
Completed2728
Not completed22262228
Withdrew: Protocol-specified criteria: study ended15241514
Withdrew: Withdrawal by subject369385
Withdrew: Death215214
Withdrew: Lost to follow-up4335
Withdrew: Noncompliance2220
Withdrew: Disease progression1820
Withdrew: Ineligibility determined1014
Withdrew: Other1411
Withdrew: Adverse event99
Withdrew: Administrative decision16
Withdrew: Protocol deviation10

Outcome measures

PrimaryBone Metastasis-free Survival (BMFS)

BMFS time was defined as the time interval from the randomization date to the first occurrence of bone metastasis or death from any cause, whichever came first. Participants last known to be alive with no bone metastasis were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first occurrence of bone metastasis before randomization were censored at their randomization date. Bone metastasis must have been confirmed by central imaging analysis or by biopsy, Evidence of disseminated tumor cells in bone marrow was not sufficient for determination of disease recurrence. Development of new primary malignancy in bone was not considered as bone metastasis. Since the median BMSF time could not be estimated due to low number of events, the percentage of participants with an event (i.e., bone metastasis or death) is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Reported as:
Number · percentage of participants
Bone Metastasis-free Survival (BMFS)
percentage of participantsPlaceboDenosumab
Bone Metastasis-free Survival (BMFS)13.5 (12.1 to 15.0)12.9 (11.6 to 14.3)
Statistical analysis
  • Placebo vs Denosumab · Stratified Log Rank · p = 0.70 · Hazard ratio (hr): 0.97 · 95% CI 0.82 to 1.14Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hazard ratio \< 1 favors denosumab.
SecondaryDisease-free Survival (DFS)

DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date. Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Reported as:
Number · percentage of participants
Disease-free Survival (DFS)
percentage of participantsPlaceboDenosumab
Disease-free Survival (DFS)19.2 (17.6 to 20.8)19.6 (18.0 to 21.2)
Statistical analysis
  • Placebo vs Denosumab · Stratified Log Rank · p = 0.57 · Hazard ratio (hr): 1.04 · 95% CI 0.91 to 1.19Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hzard ratio \< 1 favors denosumab.
SecondaryDisease-free Survival (DFS) in the Postmenopausal Subset

DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date. Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time in the postmenopausal subset could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Reported as:
Number · percentage of participants
Disease-free Survival (DFS) in the Postmenopausal Subset
percentage of participantsPlaceboDenosumab
Disease-free Survival (DFS) in the Postmenopausal Subset18.6 (16.3 to 20.9)20.3 (17.8 to 22.7)
Statistical analysis
  • Placebo vs Denosumab · Stratified Log Rank · p = 0.26 · Hazard ratio (hr): 1.12 · 95% CI 0.92 to 1.36Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hazard ratio \< 1 favors denosumab.
SecondaryOverall Survival

Overall survival (OS) time was defined as the time interval from the randomization date to the date of death from any cause. Participants last known to be alive were censored at their last contact date. Since the median time to overall survival could not be estimated at the time of the final analysis due to low numbers of events, the percentage of participants with an event (i.e., death) is reported.

Time frame:
From randomization until the end of study; median (minimum, maximum) time on study was 72.7 (0, 92) and 72.3 (0, 92) months in each treatment group respectively.
Reported as:
Number · percentage of participants
Overall Survival
percentage of participantsPlaceboDenosumab
Overall Survival9.5 (8.3 to 10.8)9.5 (8.3 to 10.7)
Statistical analysis
  • Placebo vs Denosumab · Stratified Log Rank · p = 0.94 · Hazard ratio (hr): 1.01 · 95% CI 0.83 to 1.22Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hazard ratio \< 1 favors denosumab.
SecondaryDistant Recurrence-free Survival

Distant recurrence-free survival (DRFS) was defined as the time interval from the randomization date to the date of first observation of distant disease recurrence or death from any cause, whichever came first. Participants last known to be alive, who had not experienced distant disease recurrence, were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first distant recurrence before randomization were censored at their randomization date. Distant disease recurrence includes confirmed bone metastasis and extraosseous disease other than local-regional disease recurrence. Development of non-breast cancer new primary malignancy was not considered as distant disease recurrence. Since the median time to DRFS could not be estimated due to the low number of events, the percentage of participants with an event (i.e., distant recurrence or death) is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Reported as:
Number · percentage of participants
Distant Recurrence-free Survival
percentage of participantsPlaceboDenosumab
Distant Recurrence-free Survival18.0 (16.4 to 19.6)18.7 (17.1 to 20.3)
Statistical analysis
  • Placebo vs Denosumab · Stratified Log Rank · p = 0.41 · Hazard ratio (hr): 1.06 · 95% CI 0.92 to 1.21Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hazard ratio \< 1 favors denosumab.

Adverse events

Collected over All-cause mortality includes deaths from first dose of study drug to the end of study date; median (min, max) time on study was 72.7 (0, 92) and 72.3 (0, 92) months for Placebo/Denosumab respectively. Adverse Events are from first dose of study drug to 30 days after last dose; median (min, max) time on treatment was 59.4 (0.7, 67) and 59.3 (0.7, 67) months for Placebo/Denosumab respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo215/2,218 (9.7%)675/2,218 (30.4%)2,123/2,218 (95.7%)
Denosumab215/2,241 (9.6%)702/2,241 (31.3%)2,149/2,241 (95.9%)
Most frequent serious events
Showing 10 of 706
Most frequent serious events
EventPlaceboDenosumab
Febrile neutropeniaBlood and lymphatic system disorders114/221883/2241
PyrexiaGeneral disorders33/221837/2241
NeutropeniaBlood and lymphatic system disorders36/221835/2241
CellulitisInfections and infestations30/221834/2241
PneumoniaInfections and infestations30/221827/2241
Osteonecrosis of jawMusculoskeletal and connective tissue disorders0/221830/2241
DiarrhoeaGastrointestinal disorders24/221815/2241
VomitingGastrointestinal disorders13/221824/2241
Pulmonary embolismRespiratory, thoracic and mediastinal disorders20/221817/2241
Breast cellulitisInfections and infestations18/221820/2241
Most frequent other events
Showing 10 of 68
Most frequent other events
EventPlaceboDenosumab
NauseaGastrointestinal disorders1095/22181145/2241
ArthralgiaMusculoskeletal and connective tissue disorders974/2218973/2241
AlopeciaSkin and subcutaneous tissue disorders923/2218938/2241
FatigueGeneral disorders893/2218901/2241
Hot flushVascular disorders645/2218669/2241
DiarrhoeaGastrointestinal disorders638/2218660/2241
ConstipationGastrointestinal disorders635/2218626/2241
HeadacheNervous system disorders567/2218527/2241
Pain in extremityMusculoskeletal and connective tissue disorders545/2218570/2241
Back painMusculoskeletal and connective tissue disorders486/2218563/2241

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDenosumabTotal
Mean51.6 ± 10.651.4 ± 10.751.5 ± 10.7
Age, Customized
Age, Customized(Participants)PlaceboDenosumabTotal
18 - 64 years196019593919
65 - 74 years259260519
75 - 84 years333669
≥ 85 years112
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumabTotal
Female225322564509
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumabTotal
White169216763368
Asian222213435
Japanese134135269
Hispanic/Latino112135247
Black7074144
Native Hawaiian or Other Pacific Islander437
American Indian or Alaska Native101
Other182038
Menopausal Status
Menopausal Status(Participants)PlaceboDenosumabTotal
Premenopausal116511952360
Postmenopausal108810612149
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)PlaceboDenosumabTotal
0 (Fully active)191319223835
1 (Restricted but ambulatory)340329669
2 (Ambulatory, unable to work)033
Missing022
Breast Cancer Therapy / Lymph Node Status (Strata per Randomization)
Breast Cancer Therapy / Lymph Node Status (Strata per Randomization)(Participants)PlaceboDenosumabTotal
Neo-adjuvant therapy / any lymph node status5505521102
Adjuvant therapy / lymph node negative6865133
Adjuvant therapy / lymph node positive163516393274
Hormone Receptor Status (Strata per Randomization)
Hormone Receptor Status (Strata per Randomization)(Participants)PlaceboDenosumabTotal
ER and/or PR positive174017473487
ER and PR negative5135091022

6 further baseline measures are reported on the registry.

08

Study locations

459 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Jonesboro, Arkansas 72401, United States
  • Research Site
    Alhambra, California 91801, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Campbell, California 95008, United States
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    La Verne, California 91750, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90095-1772, United States
  • Research Site
    Northridge, California 91328, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Denver, Colorado 80220, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Coral Springs, Florida 33065, United States
  • Research Site
    Fort Lauderdale, Florida 33316, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Melbourne, Florida 32901, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Cedar Rapids, Iowa 52402, United States
  • Research Site
    Hutchinson, Kansas 67502, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Danvers, Massachusetts 01923, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Saint Louis Park, Minnesota 55426, United States
  • Research Site
    Jackson, Mississippi 39202, United States
  • Research Site
    Jefferson City, Missouri 65109, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Lebanon, New Hampshire 03756-0001, United States
  • Research Site
    Denville, New Jersey 07834, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    East Setauket, New York 11733, United States
  • Research Site
    New York, New York 10003, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Nyack, New York 10960, United States
  • Research Site
    Asheville, North Carolina 28806, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Tulsa, Oklahoma 74136, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Pawtucket, Rhode Island 02860, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Columbia, South Carolina 29210, United States
  • Research Site
    Hilton Head Island, South Carolina 29926, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Abilene, Texas 79606-5208, United States
  • Research Site
    Corpus Christi, Texas 78463, United States
  • Research Site
    Dallas, Texas 75230-2510, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Garland, Texas 75042, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Plano, Texas 75075, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Richlands, Virginia 24641, United States
  • Research Site
    Richmond, Virginia 23230, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Seattle, Washington 98109-1023, United States
  • Research Site
    Seattle, Washington 98133, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Research Site
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Research Site
    San Martin, Buenos Aires B1650BOB, Argentina
  • Research Site
    Neuquen, Neuquén Q8300HDH, Argentina
  • Research Site
    Provincia De Santa Fe, Santa Fe S3000FFV, Argentina
  • Research Site
    San Miguel de Tucuman, Tucuman T4000GTB, Argentina
  • Research Site
    Camperdown, New South Wales 2050, Australia

Showing the first 100 of 459 sites across 39 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2. PubMed 31806543 ↗
  • Coleman R, Zhou Y, Jandial D, Cadieux B, Chan A. Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Adv Ther. 2021 Aug;38(8):4569-4580. doi: 10.1007/s12325-021-01812-9. Epub 2021 Jun 29. PubMed 34185259 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2010 to primary completion in Aug 2017, 86 months.

Results were first posted in Oct 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2010
First posted
Feb 26, 2010
StartActual
Jun 2, 2010
Primary completionActual
Aug 31, 2017
CompletionActual
Mar 26, 2018
Results first posted
Oct 3, 2018
Last update
Sep 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01077154
Lead sponsor
Amgen
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 26, 2010
Start date
Jun 2, 2010
Primary completion
Aug 31, 2017
Completion
Mar 26, 2018
Results posted
Oct 3, 2018
Last update
Sep 28, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion